Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

MLA

Hope S. Rugo, et al. “Author Correction: Safety Analyses from the Phase 3 ASCENT Trial of Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.” Npj Breast Cancer, vol. 10, no. 1, June 2024, p. 1. EBSCOhost, https://doi.org/10.1038/s41523-024-00650-6.

APA

Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A. Hurvitz, Joyce O’Shaughnessy, Javier Cortés, Véronique Diéras, Lisa A. Carey, Luca Gianni, Martine J. Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, & Kevin Kalinsky. (2024). Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. Npj Breast Cancer, 10(1), 1. https://doi.org/10.1038/s41523-024-00650-6

Chicago

Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A. Hurvitz, Joyce O’Shaughnessy, et al. 2024. “Author Correction: Safety Analyses from the Phase 3 ASCENT Trial of Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.” Npj Breast Cancer 10 (1): 1. doi:10.1038/s41523-024-00650-6.